Six-minute Walk Test As Clinical End Point in Cardiomyopathy Clinical Trials, Including ATTR-CM: a Systematic Literature Review

Overview

Journal J Comp Eff Res

Specialty Health Services

Date 2024 Jun 13

PMID 38869839

Authors

Jose Nativi-Nicolau

Ali Yilmaz

Noel Dasgupta

Richard Macey

James Cochrane

Judith Peatman

Catherine Summers

Jennifer Luth

Ronald Zolty

Affiliations

Soon will be listed here.

Abstract

The six-minute walk test (6MWT) is a common measure of functional capacity in patients with heart failure (HF). Primary clinical study end points in cardiomyopathy (CM) trials, including transthyretin-mediated amyloidosis with CM (ATTR-CM), are often limited to hospitalization and mortality. To investigate the relationship between the 6MWT and hospitalization or mortality in CM, including ATTR-CM. A PRISMA-guided systematic literature review was conducted using search terms for CM, 6MWT, hospitalization and mortality. Forty-one studies were identified that reported 6MWT data and hospitalization or mortality data for patients with CM. The data suggest that a greater 6MWT distance is associated with a reduced risk of hospitalization or mortality in CM. The 6MWT is an accepted alternative end point in CM trials, including ATTR-CM.

References

Vrtovec B, Poglajen G, Sever M, Zemljic G, Frljak S, Cerar A . Effects of Repetitive Transendocardial CD34 Cell Transplantation in Patients With Nonischemic Dilated Cardiomyopathy. Circ Res. 2018; 123(3):389-396. DOI: 10.1161/CIRCRESAHA.117.312170. View

Xiao W, Guo S, Gao C, Dai G, Gao Y, Li M . A Randomized Comparative Study on the Efficacy of Intracoronary Infusion of Autologous Bone Marrow Mononuclear Cells and Mesenchymal Stem Cells in Patients With Dilated Cardiomyopathy. Int Heart J. 2017; 58(2):238-244. DOI: 10.1536/ihj.16-328. View

Grogan M, Scott C, Kyle R, Zeldenrust S, Gertz M, Lin G . Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. J Am Coll Cardiol. 2016; 68(10):1014-20. DOI: 10.1016/j.jacc.2016.06.033. View

Abraham W, Aggarwal S, Prabhu S, Cecere R, Pamboukian S, Bank A . Ambulatory extra-aortic counterpulsation in patients with moderate to severe chronic heart failure. JACC Heart Fail. 2014; 2(5):526-33. DOI: 10.1016/j.jchf.2014.04.014. View

Ruberg F, Maurer M, Judge D, Zeldenrust S, Skinner M, Kim A . Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012; 164(2):222-228.e1. DOI: 10.1016/j.ahj.2012.04.015. View

Heresi G, Dweik R . Strengths and limitations of the six-minute-walk test: a model biomarker study in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011; 183(9):1122-4. DOI: 10.1164/rccm.201012-2079ED. View

Grundtvig M, Eriksen-Volnes T, Orn S, Slind E, Gullestad L . 6 min walk test is a strong independent predictor of death in outpatients with heart failure. ESC Heart Fail. 2020; 7(5):2904-2911. PMC: 7524091. DOI: 10.1002/ehf2.12900. View

Toledo C, Schwartzmann P, Silva L, da Silva Ferreira G, Bianchini Cardoso F, Ribeiro V . Serum potassium levels provide prognostic information in symptomatic heart failure beyond traditional clinical variables. ESC Heart Fail. 2021; 8(3):2133-2143. PMC: 8120348. DOI: 10.1002/ehf2.13295. View

Vong C, Boucher M, Riley S, Harnisch L . Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis. Am J Cardiovasc Drugs. 2021; 21(5):535-543. PMC: 8435516. DOI: 10.1007/s40256-021-00464-y. View

10.

Bittner V, Weiner D, Yusuf S, Rogers W, McIntyre K, Bangdiwala S . Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. JAMA. 1993; 270(14):1702-7. View

11.

Oginezawa S, Ishihara T, Iwafuchi Y, Hatano Y, Kashimura K, Onodera O . [ATTRv amyloidosis with early improvement demonstrated by the 6-minute walk test following Patisiran therapy: a case report]. Rinsho Shinkeigaku. 2022; 62(5):375-379. DOI: 10.5692/clinicalneurol.cn-001693. View

12.

Benson M, Dasgupta N, Rissing S, Smith J, Feigenbaum H . Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy. Amyloid. 2017; 24(4):219-225. DOI: 10.1080/13506129.2017.1374946. View

13.

Hajahmadi M, Shemshadi S, Khalilipur E, Amin A, Taghavi S, Maleki M . Muscle wasting in young patients with dilated cardiomyopathy. J Cachexia Sarcopenia Muscle. 2017; 8(4):542-548. PMC: 5566643. DOI: 10.1002/jcsm.12193. View

14.

Diaz-Navarro R, Urrutia G, Cleland J, Poloni D, Villagran F, Acosta-Dighero R . Stem cell therapy for dilated cardiomyopathy. Cochrane Database Syst Rev. 2021; 7:CD013433. PMC: 8406792. DOI: 10.1002/14651858.CD013433.pub2. View

15.

Yungher F, Kim A, Boehme A, Kleyman I, Weimer L, Maurer M . Peripheral neuropathy symptoms in wild type transthyretin amyloidosis. J Peripher Nerv Syst. 2020; 25(3):265-272. DOI: 10.1111/jns.12403. View

16.

Godino C, Scotti A, Taramasso M, Adamo M, Russo M, Chiarito M . Two-year cardiac mortality after MitraClip treatment of functional mitral regurgitation in ischemic and non-ischemic dilated cardiomyopathy. Int J Cardiol. 2018; 269:33-39. DOI: 10.1016/j.ijcard.2018.06.041. View

17.

Vrtovec B, Poglajen G, Lezaic L, Sever M, Domanovic D, cernelc P . Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circ Res. 2012; 112(1):165-73. DOI: 10.1161/CIRCRESAHA.112.276519. View

18.

Sattianayagam P, Hahn A, Whelan C, Gibbs S, Pinney J, Stangou A . Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J. 2011; 33(9):1120-7. DOI: 10.1093/eurheartj/ehr383. View

19.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

20.

Pulido V, Doros G, Berk J, Sanchorawala V . The six-minute walk test in patients with AL amyloidosis: a single centre case series. Br J Haematol. 2017; 177(3):388-394. DOI: 10.1111/bjh.14586. View